Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 488 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Promethazine Clear all
Active, not recruiting Phase 3 Interventional

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT02375204
View directory record Official record
Conditions
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
Interventions
paclitaxel, ifosfamide, cisplatin, pegylated G-CSF, G-CSF, carboplatin, etoposide phosphate, stem cell reinfusion
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
14 Years and older · Male only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

NCT05211336
View directory record Official record
Conditions
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
Interventions
Obinutuzumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib, Acetaminophen, Diphenhydramine, Peg-filgrastim, CT Scan (chest, abdomen, and pelvis), MRI, 18f-FDG-PET, PET, Lumbar puncture/Ommaya tap, Bone marrow aspiration/biopsy, EKG
Drug · Other · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 1 Interventional

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

NCT04765449
View directory record Official record
Conditions
Covid19
Interventions
Cytotoxic T Lymphocytes
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 8:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Losartan to Improve Hip Microfracture

NCT04212650
View directory record Official record
Conditions
Hip Osteoarthritis, Hip Impingement Syndrome, Cartilage Damage, Fibrosis
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 20, 2026, 8:02 PM EDT
Recruiting Phase 3 Interventional

Novel Strategies for Reducing Burn Scar Itch

NCT06801626
View directory record Official record
Conditions
Burn Scar, Itch Scarring, Wound
Interventions
Famotidine and 4% topical cromolyn sodium, Placebo
Combination Product · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 2 Interventional Results available

Psilocybin-facilitated Treatment for Cocaine Use

NCT02037126
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Psilocybin, Diphenhydramine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 4 Interventional

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

NCT00168779
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
113
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 2 Interventional Results available

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

NCT00576758
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
obinutuzumab (RO5072759), rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

NCT01985126
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab 16 mg/kg (Part 1), Daratumumab 8 mg/kg (Part 1), Methylprednisolone, Acetaminophen, Diphenhydramine, Daratumumab (Part 2)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 4 Interventional Results available

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Hydrochlorothiazide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 4 Interventional

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

NCT00095290
View directory record Official record
Conditions
Albuminuria
Interventions
Ramipril + Irbesartan, Ramipril + Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Tustin, California • Miami, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 20, 2026, 8:02 PM EDT
Terminated Phase 3 Interventional Results available

The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine

NCT02735343
View directory record Official record
Conditions
Headache
Interventions
Compazine, Ketamine
Drug
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 20, 2026, 8:02 PM EDT
Terminated Phase 2 Interventional Results available

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

NCT00887640
View directory record Official record
Conditions
Prostate Cancer
Interventions
Temsirolimus, Diphenhydramine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Durham, North Carolina • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 20, 2026, 8:02 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Use of Driving Tests to Evaluate Patient Performance on Oral Opioids

NCT00659035
View directory record Official record
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Asokumar Buvanendran
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Recruiting Phase 2 Interventional

Trial of Zolpidem for Sleep in Children With Autism

NCT05540574
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 3 Interventional Results available

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

NCT00249795
View directory record Official record
Conditions
Atrial Fibrillation, Cardiovascular Disease
Interventions
Irbesartan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
9,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 20, 2026, 8:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

NCT06108063
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
Losartan, Placebo - Losartan
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 4 Interventional Results available

Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo

NCT02062710
View directory record Official record
Conditions
Cough Reflex Sensitivity
Interventions
diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo, dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 20, 2026, 8:02 PM EDT
Terminated Phase 2 Interventional Results available

Losartan for the Treatment of Pediatric NAFLD

NCT03467217
View directory record Official record
Conditions
NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Losartan potassium, Placebo losartan capsule
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study A

NCT00283686
View directory record Official record
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 20, 2026, 8:02 PM EDT
Terminated Phase 1 Interventional

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

NCT01292694
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Losartan, Captopril, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 20, 2026, 8:02 PM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 20, 2026, 8:02 PM EDT
Completed Phase 2 Interventional Results available

Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus

NCT01905631
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Aurstat Anti-Itch Hydrogel (Aurstat)
Drug
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
12 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 20, 2026, 8:02 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial

NCT01892995
View directory record Official record
Conditions
Suicide
Interventions
Ketamine
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 20, 2026, 8:02 PM EDT